Boston Scientific Marks Progress On Regulatory, Restructuring Efforts
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific expects FDA to lift restrictions stemming from a two-year-old corporate warning letter by mid-year following the agency's recent commencement of manufacturing site inspections, the company says
You may also be interested in...
Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches
Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter
Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches
Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter
Boston Scientific’s Taxus Liberte
Second-generation paclitaxel-eluting coronary stent system gets FDA "approvable" letter. Boston Scientific plans to launch the device soon after FDA lifts restrictions imposed by a 2006 corporate warning letter citing quality system violations. FDA is re-inspecting the firm's manufacturing facilities and the company expects the restrictions to be lifted around mid-year (1"The Gray Sheet" Feb. 11, 2008, p. 11)